Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Salicylic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.82 |
| ▸ | HPGD | P15428 | 7/20 | 0.82 |
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.82 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.82 |
| ▸ | CA12 | O43570 | 1/20 | 0.82 |
| ▸ | CA1 | P00915 | 1/20 | 0.82 |
| ▸ | CA2 | P00918 | 1/20 | 0.82 |
| ▸ | HMGB1 | P09429 | 1/20 | 0.82 |
| ▸ | CA4 | P22748 | 1/20 | 0.82 |
| ▸ | CA6 | P23280 | 1/20 | 0.82 |
| ▸ | CA7 | P43166 | 1/20 | 0.82 |
| ▸ | CA9 | Q16790 | 1/20 | 0.82 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.82 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.82 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.56 |
| ▸ | HSD17B10 | Q99714 | 5/20 | 0.53 |
| ▸ | TSHR | P16473 | 4/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 4/20 | 0.52 |
| ▸ | G6PD | P11413 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Salicylic Acid SCHEMBL1003308 | 0.93 | ALDH1A1 (0.78) | ALDH1A1HPGDKDM4ESMN1; SMN2CA12 | |
| Salicylic Acid SCHEMBL31332109 | 0.93 | ALDH1A1 (0.78) | ALDH1A1HPGDKDM4ESMN1; SMN2CA12 | |
| Salicylic Acid SCHEMBL25288775 | 0.93 | ALDH1A1 (0.78) | ALDH1A1HPGDKDM4ESMN1; SMN2CA12 | |
| Salicylic Acid SCHEMBL982280 | 0.91 | ALDH1A1 (0.75) | ALDH1A1HPGDKDM4ESMN1; SMN2CA12 | |
| Salicylic Acid SCHEMBL30297957 | 0.91 | ALDH1A1 (0.75) | ALDH1A1HPGDKDM4ESMN1; SMN2CA12 | |
| Salicylic Acid SCHEMBL30297915 | 0.91 | ALDH1A1 (0.75) | ALDH1A1HPGDKDM4ESMN1; SMN2CA12 | |
| Salicylic Acid SCHEMBL4907211 | 0.91 | ALDH1A1 (0.75) | ALDH1A1HPGDKDM4ESMN1; SMN2CA12 | |
| Salicylic Acid SCHEMBL15623328 | 0.91 | ALDH1A1 (0.75) | ALDH1A1HPGDKDM4ESMN1; SMN2CA12 | |
| Salicylic Acid SCHEMBL5874112 | 0.91 | ALDH1A1 (0.75) | ALDH1A1HPGDKDM4ESMN1; SMN2CA12 | |
| Salicylic Acid SCHEMBL10812276 | 0.91 | ALDH1A1 (0.75) | ALDH1A1HPGDKDM4ESMN1; SMN2CA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3697230-A1 | IMPROVING FOWL PRODUCTION BY ADMINISTRATION OF A SYNTHETIC BIOENSEMBLE OF MICROBES OR PURIFIED STRAINS THEREOF | Ascus Biosciences, Inc. (US) | 2020-08-26 | — | — | EP | disclosed |
| WO-2019079629-A1 | IMPROVING FOWL PRODUCTION BY ADMINISTRATION OF A SYNTHETIC BIOENSEMBLE OF MICROBES OR PURIFIED STRAINS THEREOF | ASCUS BIOSCIENCES, INC. (US) | 2019-04-25 | — | — | WO | disclosed |
| EP-1961764-B1 | SUGAR CHAIN ADDUCT OF PEPTIDE AND PHARMACEUTICAL COMPRISING THE SAME AS ACTIVE INGREDIENT | SHIONOGI & CO (JP) | 2011-05-11 | — | — | EP | disclosed |
| US-20100016547-A1 | Glycosilated Peptide and Medicine Comprising It as an Effective Ingredient | NATIONAL UNIVERSITY CORPORATION HOKKAIDO UNIVERSITY (JP) | 2010-01-21 | — | — | US | disclosed |
| EP-1961764-A1 | SUGAR CHAIN ADDUCT OF PEPTIDE AND PHARMACEUTICAL COMPRISING THE SAME AS ACTIVE INGREDIENT | Shionogi Co., Ltd. (JP) | 2008-08-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100016547-A1 | Glycosilated Peptide and Medicine Comprising It as an Effective Ingredient | GLP1R, VIP, IAPP | ALDH1A1 1989/4885HPGD 1935/4885KDM4E 1841/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.